Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial
Eur Urol. 2024 Mar 14:S0302-2838(24)02133-X.
doi: 10.1016/j.eururo.2024.02.016.
Online ahead of print.
1 Vall d'Hebron Institute of Oncology, Barcelona, Spain.
2 Vall d'Hebron Institute of Oncology, Barcelona, Spain; Vall d'Hebron University Hospital, Barcelona, Spain; Section of Innovation Biomedicine-Oncology, Department of Engineering for Innovation Medicine, University of Verona and University and Hospital Trust of Verona, Verona, Italy.
3 Vall d'Hebron Institute of Oncology, Barcelona, Spain; Vall d'Hebron University Hospital, Barcelona, Spain.
4 Fundació Puigvert, Institut de Recerca Sant Pau, Barcelona, Spain; Department of Medicine, Surgery and Pharmacy, Universitá degli Studi di Sassari, Sassari, Italy.
5 Vall d'Hebron University Hospital, Barcelona, Spain.
6 Bellvitge University Hospital, L'Hospitalet del Llobregat, Spain.
7 Bellvitge University Hospital, L'Hospitalet del Llobregat, Spain; Institut Catala d'Oncologia, L'Hospitalet del Llobregat, Spain.
8 Hospital Universitario Virgen de la Victoria and Instituto de Investigación Biomédica de Málaga-Plataforma Bionand, Malaga, Spain.
9 Hospital Doce de Octubre and Instituto de Investigacion i+12, Madrid, Spain.
10 Vall d'Hebron Institute of Oncology, Barcelona, Spain; Vall d'Hebron University Hospital, Barcelona, Spain. Electronic address: jmateo@vhio.net.
11 Vall d'Hebron Institute of Oncology, Barcelona, Spain. Electronic address: rperez@vhio.net.